SynopsisSwedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. The global Swedish Porphyria Drugs market was .....
SynopsisSwedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. The global Swedish Porphyria Treatment market .....
SynopsisSwedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. The global Swedish Porphyria Therapeutics mark.....
SynopsisNelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Nelarabine market was valued at US$ 134 million in 2023 and is anticipated to reach US$ 146.3 million by 2030, witnessing a CAGR of 1.1% during the forecast period .....
SynopsisArranon is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Arranon market was valued at US$ 79 million in 2023 and is anticipated to reach US$ 85 million by 2030, witnessing a CAGR of 1.2% during the forecast period 2024-2030......
SynopsisAtriance is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Atriance market was valued at US$ 56 million in 2023 and is anticipated to reach US$ 62 million by 2030, witnessing a CAGR of 1.1% during the forecast period 2024-203.....
SynopsisInotuzumab ozogamicin is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The global Inotuzumab Ozogamicin market was valued at US$ 219 million in 2023 and is anticipated to reach US$ 40.....
SynopsisBesponsa is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The global Besponsa market was valued at US$ 219 million in 2023 and is anticipated to reach US$ 405.9 million by 2030, witne.....
SynopsisEnasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Enasidenib market wa.....
SynopsisEnasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Enasidenib Drugs mar.....
